Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Deucravacitinib

FDA-approved product (tablet, oral), marketed as Sotyktu.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Deucravacitinib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Psoriasis
  • Psoriasis vulgaris

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Janus-associated kinase (jak) inhibitors
FDA pharmacologic class
Tyrosine Kinase 2 Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA53.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli34.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae23.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis61.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Deucravacitinib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.5 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.6 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Deucravacitinib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment

    NCT04908189 · start 2021-07-15

    Registered record
    Registry ID
    NCT04908189
    Conditions
    Psoriatic Arthritis
    Interventions
    Deucravacitinib; Placebo; Apremilast
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2021-07-15
    Completion
    2026-11-12
    Enrolment
    729

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsoriatic Arthritis
    InterventionDeucravacitinib; Placebo; Apremilast
    PhasePhase 3
    Registry statusActive not recruiting

  • A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Active Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)

    NCT04857034 · start 2021-07-12

    Registered record
    Registry ID
    NCT04857034
    Conditions
    Lupus Erythematosus, Discoid; Lupus Erythematosus, Subacute Cutaneous
    Interventions
    Deucravacitinib; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2021-07-12
    Completion
    2028-02-28
    Enrolment
    74

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLupus Erythematosus, Discoid; Lupus Erythematosus, Subacute Cutaneous
    InterventionDeucravacitinib; Placebo
    PhasePhase 2
    Registry statusActive not recruiting

  • A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Children and Adolescent Participants With Moderate to Severe Plaque Psoriasis

    NCT04772079 · start 2021-03-23

    Registered record
    Registry ID
    NCT04772079
    Conditions
    Plaque Psoriasis
    Interventions
    Deucravacitinib; Placebo matching deucravacitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2021-03-23
    Completion
    2033-09-08
    Enrolment
    153

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPlaque Psoriasis
    InterventionDeucravacitinib; Placebo matching deucravacitinib
    PhasePhase 3
    Registry statusRecruiting

  • A Study of the Safety, Efficacy, and Biomarker Response of BMS-986165 in Participants With Moderate to Severe Ulcerative Colitis

    NCT04613518 · start 2021-03-15

    Registered record
    Registry ID
    NCT04613518
    Conditions
    Colitis, Ulcerative
    Interventions
    BMS-986165; Placebo Comparator
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2021-03-15
    Completion
    2023-11-29
    Enrolment
    38

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColitis, Ulcerative
    InterventionBMS-986165; Placebo Comparator
    PhasePhase 2
    Registry statusCompleted

  • Pharmacokinetics (Drug Levels in Blood) of BMS-986165 When Taken as Various Solid Tablet Prototypes by Healthy Participants

    NCT04249284 · start 2020-02-06

    Registered record
    Registry ID
    NCT04249284
    Conditions
    Healthy Participants
    Interventions
    BMS-986165; BMS-986165 prototype 1; BMS-986165 prototype 2
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2020-02-06
    Completion
    2020-03-15
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Participants
    InterventionBMS-986165; BMS-986165 prototype 1; BMS-986165 prototype 2
    PhasePhase 1
    Registry statusCompleted

  • A Study Comparing the Effects of Famotidine Pretreatment and of Food on the Relative Bioavailability of BMS-986165 in Healthy Volunteers

    NCT04209699 · start 2019-12-27

    Registered record
    Registry ID
    NCT04209699
    Conditions
    Healthy Participants
    Interventions
    BMS-986165; Famotidine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2019-12-27
    Completion
    2020-02-11
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Participants
    InterventionBMS-986165; Famotidine
    PhasePhase 1
    Registry statusCompleted

  • An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo in Participants With Plaque Psoriasis (POETYK-PSO-3) in Mainland China, Taiwan, and South Korea

    NCT04167462 · start 2019-11-25

    Registered record
    Registry ID
    NCT04167462
    Conditions
    Psoriasis
    Interventions
    BMS-986165; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2019-11-25
    Completion
    2022-01-07
    Enrolment
    220

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsoriasis
    InterventionBMS-986165; Placebo
    PhasePhase 3
    Registry statusCompleted

  • The Effects Diflunisal on the Levels of BMS-986165 in Healthy Participants

    NCT04113668 · start 2019-10-01

    Registered record
    Registry ID
    NCT04113668
    Conditions
    Healthy Participants
    Interventions
    BMS-986165; diflunisal
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2019-10-01
    Completion
    2019-11-25
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Participants
    InterventionBMS-986165; diflunisal
    PhasePhase 1
    Registry statusCompleted

  • An Investigational Study to Determine the Drug Level Profile of BMS-986165 in Healthy Male Volunteers Following Transporter Inhibition.

    NCT04086719 · start 2019-09-12

    Registered record
    Registry ID
    NCT04086719
    Conditions
    Healthy Male Volunteers
    Interventions
    BMS-986165; Pyrimethamine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2019-09-12
    Completion
    2019-10-29
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Male Volunteers
    InterventionBMS-986165; Pyrimethamine
    PhasePhase 1
    Registry statusCompleted

  • A Study to Investigate the Effects of Cytochrome P450 1A2 Induction by Ritonavir on BMS-986165 Drug Levels and Effects in Healthy Participants

    NCT04055506 · start 2019-08-14

    Registered record
    Registry ID
    NCT04055506
    Conditions
    Healthy Participants
    Interventions
    BMS-986165; Ritonavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2019-08-14
    Completion
    2019-09-21
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Participants
    InterventionBMS-986165; Ritonavir
    PhasePhase 1
    Registry statusCompleted

  • Safety and Efficacy of Deucravacitinib in Participants With Moderate to Severe Ulcerative Colitis

    NCT03934216 · start 2019-07-01

    Registered record
    Registry ID
    NCT03934216
    Conditions
    Ulcerative Colitis
    Interventions
    BMS-986165; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2019-07-01
    Completion
    2023-04-04
    Enrolment
    131

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUlcerative Colitis
    InterventionBMS-986165; Placebo
    PhasePhase 2
    Registry statusCompleted

  • A Study to Investigate the Effects of Gastric Acid Suppression by Rabeprazole and BMS-986165 on How Fast and Complete The Drug is Absorbed Into the Body of Healthy Participants

    NCT03979248 · start 2019-05-16

    Registered record
    Registry ID
    NCT03979248
    Conditions
    Healthy
    Interventions
    BMS-986165; Rabeprazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2019-05-16
    Completion
    2019-07-07
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionBMS-986165; Rabeprazole
    PhasePhase 1
    Registry statusCompleted

  • Single and Multiple Dose Pharmacokinetics of BMS-986165 in a Randomized, Double-Blind, Placebo-Controlled Study in Healthy Chinese Subjects

    NCT03956953 · start 2019-04-04

    Registered record
    Registry ID
    NCT03956953
    Conditions
    Autoimmune Diseases
    Interventions
    BMS-986165; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2019-04-04
    Completion
    2019-09-25
    Enrolment
    135

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAutoimmune Diseases
    InterventionBMS-986165; Placebo
    PhasePhase 1
    Registry statusCompleted

  • Long-Term Safety and Efficacy Study of Deucravacitinib in Participants With Systemic Lupus Erythematosus

    NCT03920267 · start 2019-03-26

    Registered record
    Registry ID
    NCT03920267
    Conditions
    Systemic Lupus Erythematosus
    Interventions
    BMS-986165
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2019-03-26
    Completion
    2025-03-21
    Enrolment
    261

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSystemic Lupus Erythematosus
    InterventionBMS-986165
    PhasePhase 2
    Registry statusCompleted

  • An Investigational Study to Evaluate Experimental Medication BMS-986165 Given as a Tablet and Solution in Healthy Male Participants

    NCT03739788 · start 2018-12-05

    Registered record
    Registry ID
    NCT03739788
    Conditions
    Healthy Participants
    Interventions
    BMS-986165
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-12-05
    Completion
    2019-02-11
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Participants
    InterventionBMS-986165
    PhasePhase 1
    Registry statusCompleted